Melinta Therapeutics Inc(MLNT)stock report

Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide therapeutic solutions. The Company’s lead product is Baxdela, an antibiotic approved by the United States food and drug administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The Company also has an extensive pipeline of preclinical and clinical stage products This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market.

Finance:
Current cash: 90.34M, Latest quarter loss:36.18M,去年亏损157M,只够烧1年。

EPS and Sales:
https://finance.yahoo.com/quote/MLNT/financials?p=MLNT

Date EPS % last year % last quarter
 2018.9.30 -2.66 99.87% 349.62%
2018.12.31 -17.12 84.33% -543.61%
 2019.3.31 -2.34 50.84% 86.33%
2019.6.30 -5.42 54.68% -131.62%

 

Date Sales % last year % last quarter
2018.12.31 60.94M 105.65% 55.92%
 2019.3.31 96.43M 184.76% 58.24%
2019.6.30 14.08M -5.10% -85.40%
 2019.9.30 30.04M 11.82% 113.35%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=MLNT&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/MLNT/institutional-ownership/

2019.10.22更新:
总机构数68家,较上期无变化
总持股数269万股,较上期无变化
持股比例19.56%,较上期无变化

Analyst Ratings:
https://www.tipranks.com/stocks/MLNT/price-targe

This Post Has One Comment

  1. Wan Joy
    Wan Joy

    廖博点评:
    MLNT扩展已批抗菌素新药新的应用范围pdufa date 10/24. 。Priority review, 治疗社区获得性肺炎,因为是已批药物,只是扩展应用范围,而且是priority review,市场急需药物。感觉获批的概率相当大。
    drawback: 不是治疗这些感染的唯一用药。但疗效和安全性都跟市面上的已有药相当。因为要避免产生抗药性,市场急需不同机制的抗菌素。这是获得priority review 的原因。

Leave a Reply